Selected article for: "complete remission and cyclophosphamide etoposide"
Author: Choi, Jung Yoon; Kang, Hyoung Jin; An, Hong Yul; Hong, Kyung Taek; Shin, Hee Young
Title: Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients
  • Cord-id: qrkuap9y
  • Document date: 2020_3_26
    • ID: qrkuap9y
    Snippet: Treatment outcomes in pediatric lymphoma have improved substantially over the past 2 decades; however, the prognosis for patients with high risk or relapsed disease remains poor. We evaluated outcomes of high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) in 56 pediatric lymphoma patients. Patients received nitrosourea (51 BCNU; 5 ACNU), etoposide, and cyclophosphamide (BEC; AEC). Median age at HDC/auto-SCT was 12 years (range 2–17 years). Forty-four patients under
    Document: Treatment outcomes in pediatric lymphoma have improved substantially over the past 2 decades; however, the prognosis for patients with high risk or relapsed disease remains poor. We evaluated outcomes of high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) in 56 pediatric lymphoma patients. Patients received nitrosourea (51 BCNU; 5 ACNU), etoposide, and cyclophosphamide (BEC; AEC). Median age at HDC/auto-SCT was 12 years (range 2–17 years). Forty-four patients underwent HDC/auto-SCT because they did not achieve complete remission after induction chemotherapy. Eight patients showed relapse and four NK/T-cell lymphoma patients also underwent HDC/auto-SCT. BCNU pneumonitis was diagnosed in nine (16.0%) patients. Eight (14.3%) relapsed after HDC/auto-SCT. Treatment-related mortality occurred in three cases. Five-year event-free survival and overall survival rates were 74.8% [72.7% non-Hodgkin’s lymphoma (NHL); 83.3% Hodgkin’s disease (HD); 72.7%] and 83.6% (81.6% NHL; 91.7% HD), respectively. HDC/auto-SCT with BEC or AEC regimen for pediatric high-risk lymphoma patients showed feasible outcomes. However, treatment modifications are warranted to reduce relapse and toxicity.

    Search related documents:
    Co phrase search for related documents
    • absolute anc neutrophil count and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • absolute anc neutrophil count and lung disease: 1, 2
    • acute lymphoblastic leukemia and logistic regression: 1
    • acute lymphoblastic leukemia and lung disease: 1, 2
    • acute myeloid leukemia and logistic regression: 1
    • acute myeloid leukemia and long term follow: 1, 2
    • acute myeloid leukemia and lung transplantation: 1
    • acute respiratory distress syndrome and log rank test kaplan meier method: 1, 2
    • acute respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and long term complication: 1, 2
    • acute respiratory distress syndrome and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory distress syndrome and long term survival: 1, 2, 3
    • acute respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung transplantation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • log rank test kaplan meier method and logistic regression: 1, 2, 3
    • log rank test kaplan meier method and long term survival: 1
    • logistic regression and long term complication: 1, 2, 3
    • logistic regression and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • logistic regression and long term period: 1, 2, 3